8 Gene Panel for Barretts Esophagus
- 8 Gene Panel for Barretts Esophagus
- 8-gene Panel for Barrett's Esophagus
- Meltzer 8-marker panel for Esophageal Adenocarcinoma
- Eight methylation biomarkers - p16, RUNX3, HPP1 (HGNC name TMEFF2), NELL1, TAC1, SST, AKAP12 and CDH13 - were tested in a restrospective multicenter double-blinded validation study for their accuracy in predicting neoplastic progression in Barretts Esophagus. Hypermethylation of p16, RUNX3 and HPP1 has been show to occur in early Barretts Esophagus-related neoplastic progression and predicts progression risk. Several of the panel (NELL1, TAC1, SST, AKAP12 and CDH13) were also shown to be methylated early and often in Barretts Esophagus-related neoplastic progression.
- QA State
- HGNC Name
- QA State for Esophagus
- Under Review
Organ-specific information for some biomarkers are currently being annotated or are "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus.
- CpG island hypermethylation in progression of esophageal and gastric cancer.
- Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
- Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors.
- Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.
- No resources were specified for this biomarker.